Mehta Vimal 4
4 · BioXcel Therapeutics, Inc. · Filed Jun 17, 2026
Research Summary
AI-generated summary of this filing
BioXcel (BTAI) CEO Vimal Mehta Receives 219 Shares via RSU Vesting
What Happened Vimal Mehta, CEO, President and a director of BioXcel Therapeutics (BTAI), had 219 restricted stock units (RSUs) convert into 219 shares of common stock on June 15, 2026. The Form 4 shows an acquisition entry for 219 shares via conversion of a derivative security and a corresponding disposition entry at $0.00 for the derivative (i.e., the RSUs ceased to exist). No cash was paid or received in this transaction — this was a vesting/conversion event, not an open-market purchase or sale.
Key Details
- Transaction date: 2026-06-15; Form 4 filed 2026-06-17 (timely filing).
- Reported entries: +219 shares acquired via conversion of derivative (code M); 219 derivative units disposed at $0.00.
- Price / value: No cash consideration reported; acquisition price N/A, disposition price $0.00.
- Shares owned after transaction: Not specified in this filing.
- Notable footnotes:
- F1: Each RSU converts to one share of common stock when vested.
- F3: The RSUs were part of a 3,500-RSU grant (granted 3/15/2023) that vests 25% after one year and 6.25% each quarter thereafter.
- F2: Some securities are held of record by BioXcel LLC; Mehta may be deemed to have beneficial ownership of holdings held by that entity but disclaims ownership except to the extent of any pecuniary interest.
Context This appears to be a routine scheduled vesting installment from a previously disclosed 3,500-RSU grant (6.25% of 3,500 ≈ 219), not a sale or purchase. For retail investors, such RSU conversions increase the insider’s reported share count but do not by themselves signal a buy or sell intent.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-06-15+219→ 69,817 total - Exercise/Conversion
Restricted Stock Units
[F1][F3]2026-06-15−219→ 1,313 total→ Common Stock (219 underlying)
- 125(indirect: By Spouse)
Common Stock
- 480,343(indirect: By LLC)
Common Stock
[F2]
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]These securities are held of record by BioXcel LLC. BioXcel LLC is a subsidiary of BioXcel Holdings, Inc. ("Parent"). The Reporting Person is an executive officer and the sole member of the board of directors of Parent and an executive officer and one of two managers on the board of managers of BioXcel LLC and Parent. By virtue of these relationships, the Reporting Person may be deemed to be the beneficial owner of the securities held of record by BioXcel LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for the purpose of Section 16 or for any other purpose.
- [F3]On March 15, 2023, the Reporting Person was granted 3,500 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.